Читать книгу Metabolic Syndrome Consequent to Endocrine Disorders - Группа авторов - Страница 27

1Pekic S, Popovic V: Expanding the cause of hypopituitarism. Eur J Endocrinol 2017;176:R269–R282.

2Van der Klaauw, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA, Pereira AM: The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 2007;156:455–462.

3Nyenwe EA, Williamson-Beddorf S, Waters B, Wan J, Solomon SS: Non-alcoholic fatty liver disease and metabolic syndrome in hypopituitary patients. Am J Med Sci 2009;338:190–195.

4Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P: Prevalence of the metabolic syndrome in adult growth hormone (GH) –deficient patients before and after GH replacement. J Clin Endocrinol Metab 2010;95:74–81.

5Verhelst J, Mattson AP, Luger A, Thunander M, Góth M, Koltowska-Häggström M, Abs R: Prevalence and characteristics of the metabolic syndrome in 2,479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2011;165:881–869.

6Luger A, Matisson A, Koltowska-Häggström M, Thunander M, Góth M, Verhelst J, Abs R: Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy a long term observational study. Diabetes Care 2012;35:57–62.

7Claessen K, Appelman-Dijkstra N, Adoptie D, Roelfsema F, Smith J, Biermasz N, Pereira A: Metabolic profile in growth hormone deficient (GHD) adults after long term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab 2013;98:352–361.

8Joustra SD, Claessen K, Dekkers O, van Beek A, Wolffenbuttel B, Pereira A, Biermasz N: High prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenoma. PLos One 2014;9:e90602.

9Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; Executive summary of the third report of the national cholesterol education programme (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.

10Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, Shepard MC, Bates AS, Stewart PM: Mortality in patients with pituitary disease. Endocrine Reviews 2010;31:301–342.

11Olsson DS, Nilsson AG, Brygelsson IL, Trimpou P, Johansson G, Andersson E: Excess mortality in women and young adults with nonfunctioning pituitary adenoma: a Sweedish Nationwide Study. J Clin Endocrinol Metab 2015;100:2651–2658.

12Tomilson JW, Holden N, Hills RK, et al: Association between premature mortality and hypopituitarism. Lancet 2001;357:425–431.

13Gaillard RC, Matisson AF, Åkerblad AC, Bengtsson BA, Cara J, Feldt-Rasmunssen U, Kotlowska-Häggström M, Monson JP, Saller B, Wilton P, Abs R: Overall and cause-specific mortality in GH-deficient adults on GH replacement. Overall and cause-specific mortality in GH-deficient patients on GH replacement. Eur J Endocrinol 2012;166:1069–1077.

14Svensson J, Bengtsson BÅ, Rosén T, Odén A, Johansson G: Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab 2004;89:3306–3312.

15Verhelst J, Kendall-Taylor P, Erfurt EM, Price DA, Geffner M, Koltowska-Häggström M, Jönsson PJ, Wilton P, Abs R: Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngeoma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database) J Clin Endocrinol Metab 2005;90:4636–4643.

16Weber M, Biller BMK, Tønnes Pedersen B, Pornara E, Christiansen JS, Höybye C: The effect of growth hormone (GH) replacement on blood glucose homeostasis in adult non-diabetic patients with GH deficiency: real-life data from the Nordinet® international outcome study. Clin Endocrinol 2017;86:192–198.

17O’Reilly MW, Reulen RC, Gupta S, Thompson CA, Dineen R, Goulden EL, Bugg G, Pearce H, Toogood AA, Gittoes NJ, Mitchell R, Thompson CJ, Ayuk J: ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: long-term follow-up of 519 patients in two large European centers. Clin Endocrinol 2016;85:748–756.

18Filipson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johansson G: The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 2006;91:3954–3961.

19Hammarstand C, Ragnarsson O, Hallén T, Andesson E, Skoglund T, Nilsson AG, Johansson G, Olsson DS: Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur J Endocrinol 2017;177:251–256.

20Filipsson H, Johansson G: GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 2008;161:S85–S95.

21Koulouri O, Auldin M, Agarwal R, Keiffer V, Robertson C, Falconer Smith J, Levy M, Howlett T: Diagnosis and treatment of hypothyroidism in TSH deficiency compared to primary thyroid disease: pituitary patients are at risk of under-replacement with levothyroxine. Clin Endocrinol (Oxf) 2011;6:744–749.

22Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, Peper M, Lubrich B, Hug MJ, Nauck M, Olschewski M, Beuchlein F, Reincke M: Thyroid hormone replacement for central hypothyroidism: a randomized controlled trial comparing two doses of thyroxin (T4) with a combination of T4 and triiodothyronine. J Clin Endocrinol Metab 2007;92:4115–4122.

23Mah PM, Webster J, Jonsson P, Feldt-Rasmunssen U, Koltowska-Häggström M, Ross RJ: Estrogen replacement in women in fertile years with hypopituitarism. J Clin Endocrinol Metab 2005;90:5964–5969.

24Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK: Oral estrogen antagonizes the metabolic action of growth hormone in growth hormone deficient women. Am J Physiol Endocrinol Metab 2001;281:E1191–E1196.

25Birzniece V, Ho K: Sex steroids and the GH axis: Implications for the management of hypopituitarism. Best Pract Res Clin Endocrinol Metab 2017;31:1–11.

26Abs R, Mattsson AF, Bengtsson BA, Feldt-Rasmunssen U, Goth MI, Koltowska-Häggström M, Monson JP, Verhelst J, Wilton P: Isolated growth hormone (GH) deficiency in adult patients: baseline characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS data base. Growth Horm IGF Res 2005;15:349–359.

27Abdu TA, Neary R, Elhadd TA, Akber M, Clayton RN: Coronary risk in growth hormone deficient adults; increased predicted risk is due largely to lipid profile abnormalities. Clin Endocrinol 2001;55:209–216.

28Van der Klaauw AA, Romijn JA, Biermasz NR, et al: Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 2006;155:702–708.

29Göthertströrm G, Svensson J, Koranyi J, et al: A prospective study of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass and metabolic indices. J Clin Endocrinol Metab 2001;86:4657–4665.

30Colson A, Brooke AM, Walker D, et al: Growth hormone deficiency and replacement in patients with treated Cushing’s disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density. Horm Res 2006;66:257–267.

31Elbornsson M, Götherström G, Bosaus I, Bengtsson BA, Johannsson G, Svensson J: Fifteen years of GH replacement improves body composition and cardiovascular risk factors. Eur J Endocrinol 2013;168:745–753.

32Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P: Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 2004;89:2192–2199.

33SpielhagenC, Schwahn C. Möller K, et al: The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Hormone IGF Res 2011;21:1–10.

34Stalenhoef AF, de Graaf J: Association of fasting glucose and non-fasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL. Curr Opin Lipidol 2008;19:355–361.

35Rizzo M, Trepp R, Bernies K, Christ ER: Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclass in patients with growth hormone deficiency before and after short-term replacement therapy. Eur J Endocrinol 2007;156:361–367.

36Salman S, Uzum AK, Telci A, Algol F, Ozbey NC: Serum adipokines and low-density lipoprotein subfraction profile in hypopituitary patients with growth hormone deficiency. Pituitary 2012;15:386–392.

37Evans LM, Davies J, Anderson R, et al: The effect of growth hormone replacement therapy on endothelial dysfunction and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000;142:254–262.

38Gonzáles-Duarte D, Madrazo-Atutxa A, Soto-Moreno A, Leal-Cerro A: Measurement of oxidative stress and endothelial dysfunction in patients with hypopituitarism and severe adult growth hormone deficiency. Pituitary 2012;15:589–597.

39Scacchi M, Valassi E, Pincelli AI, et al: Increased lipid peroxidation in adult GH-deficient patients: effect of short term GH administration. J Endocrinol Invest 2006;29:899–904.

40Monson JP, Jönsson P, Koltowska-Häggström ML, Kourides I: Growth hormone (GH) replacement decreases serum total and LDL – cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol 2007;67:623–628.

41Oliviera CR, Salvatori R, Barreto-Filho JA, et al: Insulin sensitivity and β-cell function in adults with lifetime, untreated isolated growth hormone deficiency. J Clin Endocrinol Metab 2012;97:1013–1019.

42Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO: Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 2002;87:2121–2127.

43Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L: Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 2003;88:1455–1463.

44Gillberg P, Bramnert M, Thorén M, Werner S, Johansson G: Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition and cardiovascular function. Growth Horm IGF Res 2001;11:273–281.

45Arafat AM, Möhlig M, Weickert MO, Schöfl C, Spranger J, Pfeifer AF: Improved insulin sensitivity, preserved beta cell function and improved whole-body glucose metabolism after low-dose growth hormone replacement therapy in adults with severe growth hormone deficiency: a pilot study. Diabetologia 2010;53;1304–1313.

46Giavoli C, Cappiello V, Corbetta S, et al: Different effects of short term and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults. Clin Endocrinol 2004;61:81–87.

47Joaqin C, Aguilera E, et al: Effects of GH treatment in GH-deficient adults on adiponectin, leptin and pregnancy-associated plasma protein-A. Eur J Endocrinol 2008;158:483–490.

48Abs R, Mattson AF, Thunander M, Verhelst J, Góth MI, et al: Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 2013;168:297–305.

49Attanasio AF, Jung H, Mo D, Chanson P, Bouillon R, Ho KK, Lamberts SW, Clemmons DR: Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis. J Clin Endocrinol Metab 2011;96:2255–2261.

50Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, et al: Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. Eur J Endocrinol 2012;166:13–20.

51Ukropec J, Penesová A, Skopková M, Pura M, Vlcek M, et al: Adipokine protein expression patterns in growth hormone deficiency predisposes to the increased fat cell size and whole body metabolic derangements. J Clin Endrocrinol Metab 2008;2255–2262.

52Gotherstrom G, Bengtsson BA, Bosaeus I, et al: A 10-year prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007;92:1442–1445.

53Barbosa EJ, Glad CA, Nilsson AG, Bosaeus N, Fillipson Nyström H, Svensson PA, Bengtsson BA, Nilsson S, Bosaeus I, Boguszewski L, Johansson G: Extracellular water and blood pressure in adults with growth hormone (GH) deficiency: a genotype-phenotype association study. PLos One 2014;9:1–10.

54Ahmad AM, Hopkins MT, Weston PJ, et al: Effects of GH replacement on 24 h ambulatory blood pressure and its circardian rhythm in adult GH deficiency. Clin Endocrinol 2002;56:431–437.

55Sverrisdottir YB, Elam M, Herlitz H, et al: Intense sympathetic nervous system activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998;83:1881–1885.

56Savanelli MC, Scarano E, Muscogiuri G, Barrea L, Vuolo L, Rubino M, Savastano S, Colao A, Di Somma C: Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D? Endocrine 2016;52:111–119.

57Forman JP, Williams JS, Fisher ND: Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension 2010;55:1283–1288.

58Evans LM, Davies JS, Goodfellow J, et al: Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin Endocrinol 1999;50:457–464.

59Krzyzanowska K, Mittermayer F, Schanck C, Hofer M, Woltz M, Schernthaner G: Circulating ADMA concentrations are elevated in hypopituitary adults with and without growth hormone deficiency. Eur J Clin Invest 2005;3593:208–213.

60Setola E, Monti LD, Lanzi R, et al: Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. Metabolism 2008;57:1685–1690.

61Pfeifer M, Verhoves R, Zizek B, et al: Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J Clin Endocrinol Metab 1999;50:453–457.

62Kvasnicka J, Marek J, Kvasnicka T, et al: Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone deficient adults and their modulation by recombinant human GH replacement. Clin Endocrinol (Oxf) 2000;52:543–548.

63Sartorio A, Cattaneo M, Bucciarelli P, et al: Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp Clin Endocrinol Diabetes 2000;108:486–492.

64Sesmilo G, Biller BM, Lievadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone administration on inflammation and other cardiovascular risk markers in men with growth hormone deficiency, a randomized, controlled, clinical trial. Ann Intern Med 2000;133:111–122.

65Sesmilo G, Biller BM, Lievadot J, Hayden D, Hanson G, Rifai N, Klibanski A: Effects of growth hormone (GH) administration on homocysteine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab 2001;86:1518–1524.

66Johansson JO, Landin K, Johansson G, Tengborn L, Bengtsson BA: Long treatment with growth hormone decreases plasminogen activator inhibitor and tissue plasminogen activator in growth hormone deficient adults. Thromb Haemost 1996;76:422–428.

67Devin JK, Blevins LS, Verity DK, Chen Q, Bloodworth JR, Covington J, Vaughan DE: Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J Clin Endocrinol Metab 2007;92:3633–3639.

68Di Minno MN, Palmieri V, Lombardi G, Pezzulo S, Cirillo F, Di Somma C, Valle D, Di Minno G: Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. Thromb Res 2009;124:711–713.

69Miljic D, Miljic P, Doknic M, Pekic S, M Stojanovic, Cvijovic G, Micic D, Popovic V: Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency. Growth Horm IGF Res 2013;23:243–248.

70Mc Callum RW, Sainsbury CA, Spiers A, et al: Growth hormone replacement induces decrease of C-reactive protein and large artery stiffness but does not alter endothelial function in patients with adult growth hormone deficiency. Clin Endocrinol 2005;62:473–479.

71Bollerslev J, Ueland T, Jørgenssen AP, et al: Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006;154:537–543.

72Colao A, Marzullo C, Di Somma C, Lombardi G: Growth hormone and the heart. Clin Endocrinol 2001;54:137–154.

73Widdowson WM, Gibney J: The effect of growth hormone replacement on exercise capacity in patients with GH deficiency: a meta-analysis. J Clin Endocrinol Metab 2008;93:4413–4417.

74Nass R, Huber RM, Klauss V, Muller OA, Schopohl J, Strasbubrger CJ: Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and plumonary function in patients with GH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995;80:552–557.

75Cenci MC, Soares DV, Spina LD, de Lima Oliviera Brasil RR, Lobo PM, Mansur VA, Gold J, Michmacher E, Vaisman M, Conceicao FL: Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 2009;12:322–329.

76Thomas JD, Dattani A, Zemrak F, Burchell T, Akker SA, Gurnell M, Grossman AB, Davies LC, Korbonits M: Characterization of myocardial structure and function in adult- onset growth hormone deficiency using cardiac magnetic resonance. Endocrine 2016;54:778–787.

77Elgzyri T, Castenfors J, Hagg E, Backman C, Thoren M, Bramnert M: The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency. Clin Endocrinol 2004;61:113–122.

78Andersson M, Faber J, Kjaer A, Petersen CL, Kristiansen LO: Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary 2011;14:1–10.

79Klose M, Jonsson B, Abs R, Popovic V, Koltowska-Häggström M, Saller B, Feldt-Rasmunssen U, Kourides I: From isolated GH deficiency to multiple pituitary hormone deficiencies: an evolving continuum – a KIMS analysis. Eur J Endocrinol 2009;161:S75–S83.

80Melmed S: Idiopathic adult growth hormone deficiency. J Clin Endocrinol Metab 2013;98:2187–2197.

81Nishikawa H, Iguchi G, Murawaki A, Fukoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M,Seo Y, Yano Y, Kitazawa R, Kitazawa S, Koga M, Okimura Y,Chihara K, Takahashi Y: Nonalcocholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. Eur J Endocrinol 2012;167:67–74.

82Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Di Girolamo DJ, Kopchick JJ, Le Rioth D, Trucco M, Sperling MA: Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem 2009;284:19937–19944.

83Sos BC, Harris C, Nordstrom SM, Tran JL, Balazs M, Caplazi P, Febbraio M, Applegate MA, wagner KU, Weiss EJ: Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2. J Clin Invest 2011;121:1412–1423.

84Barclay JI, Nelson CN, Ishikawa M, Murry LA, Kerr LM, McPhee TR, Powell EE, Waters MJ: GH dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011;152:181–192.

85Sobrevals L, Rodriguez C, Romero-Trevejo JL, Gondi G, Monreal I, Paneda A, Juanarena N, Arclus S, Rasquin N, Guembe I, Gonsalez-Aseguinolaza G, Prieto J, Fortes P: Insulin like growth factor-1 gene transfer to cirrhotic liver induces fibrinolysis and reduces fibrinogenesis leading to cirrhosis reversion in rats. Hepatology 2010;51:912–921.

86Swords FM, Caroll PV, Kisalu J, Wood PJ, Taylor NF, Monson JP: The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol 2003;59:613–620.

87Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH, Salvatori R, Samuels MH: Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2016;101:3888–3921.

88Esteban NV, Loughlin T, Yergey AI, Zewadski JK, Booth JD, Winterer JC, Loriaux DL: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991;72:39–45.

89Danilowics K, Bruno OD, Manavela M, Gomez RM, Barkan A: Correction of cortisol over-replacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008;11:279–285.

90Murry R, Ekman B, Fitts D, Marelli C, Quinkler M, Zelissen P: Effects of adrenal insufficiency on body composition and metabolic indices: data from the European Adrenal Insufficiency Registry (EU-AIR) Endocrine abstracts ECE 2014 volume 35, P55.

91Johansson G, Nilsson AG, Bergthorsdottir R, Burman P, Dalqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlber J, Biller BM, Monson JP, Stewart PM, Lennernas H, Skrtic S: Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual release formulation. J Clin Endocrinol Metab 2012;97:473–481.

92Grossman A, Johansson G, Quinkler M, Zelissen P: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur J Endocrinol 2013;169:R165–175.

93Persani L, Ferretti E, Borgato S, Faglia G, Beck-Pecoz P: Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000;85:3631–3635.

94Beck-Peccoz P, Rodari G, Giavoli G, Lania A: Central hypothyroidism – a neglected thyroid disorder. Nat Rev Endocrinol 2017;10:588–598.

95Losa M, Scavini M, Gatti E, Rossini A, Madaschi S, Formenti I, Caumo A, Stidley CA, Lanzi R: Long-term effects of growth hormone replacement therapy on thyroid function in adults with growth hormone deficiency. Thyroid 2008;18:1249–1254.

96Phelan N, Conway SH, Liahana S, et al: Quantification of the adverse effect of ethynil estradiol containing oral contraceptive pills when used in conjunction with growth hormone replacement in routine practice. Clin Endocrinol 2011;76:729–733.

97Pappachan JM, Raskauskiene D, Kutty VR, Clayton RN: Excess mortality associated with hypopituitarism in adults: a meta-analysis of observational studies. J Clin Endocrinol Metab 2015;100:1405–1411.

98Olsson DS, Nilsson AG, Bryngelsson IL, Trimpou P, Johansson G, Andersson E: Excess mortality in women and young adults with non-functioning pituitary adenoma: a Swedish nationwide study. J Clin Endocrinol Metab 2015,100:2651–2658.

99Olsson DS, Bryngelsson IL, Ragnarsson O: Time trends of mortality in patients with nonfunctioning pituitary adenoma: a Swedish nationwide study. Pituitary 2017;20:218–224.

100Child CJ, Conroy D, Zimmermann AG, Woodmansee WW, Erfurt EM, Robison LL: Incidence of primary cancers and intracranial tumor recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the hypopituitary control and complications study. Eur J Endocrinol 2015;172:779–790.

101Jasim S, Alahdab F, Ahmed AT, Tamhane SU, Sharma A, Donegan D, Nippoldt TB, Murad MH: The effect of growth hormone replacement in patients with hypopituitarism on pituitary tumor recurrence, secondary cancer and stroke. Endocrine 2017;56:33–42.

102De Gregorio C, Andó G, Canavó S, Cotta OR, Trio O, Cusma Piccone M, Trimarchi F, Curtó L: Cardiovascular outcomes and conventional risk factors in non-diabetic adult patients with GH deficiency: a long-term prospective cohort study. Eur J Intern Med 2015;26:813–818.

103Olsson DS, Trimpou P, Hallén T, Bryngelsson IL, Andersson E, Skoglund T, Bengsston BA, Johansson G, Nilsson AG: Life expectancy in patients with pituitary adenoma receiving growth hormone replacement. Eur J Endocrinol 2017;176:67–75.

104de Haas et al: The metabolic syndrome in cancer survivors. Lancet Oncol 2010;11:193–203.

Prof. Vera Popovic

Belgrade School of Medicine, University of Belgrade

Dr Subotica 6

Belgrade 11 000 (Serbia)

E-Mail popver@gmail.com